A novel human laboratory model for screening medications for alcohol use disorder

Diana Ho, Brandon Towns, Erica N Grodin, Lara A Ray, Diana Ho, Brandon Towns, Erica N Grodin, Lara A Ray

Abstract

Background: Alcohol use disorder (AUD) is a highly prevalent, chronic relapsing disorder with a high disease burden in the USA. Pharmacotherapy is a promising treatment method for AUD; however, the few FDA-approved medications are only modestly effective. Medications development for AUD is a high priority research area, but the cumbersome drug development process hinders many potential compounds from reaching approval. One area with major opportunities for improvement is the process of screening novel compounds for initial efficacy, also known as early phase 2 trials. Early phase 2 trials incorporate human laboratory paradigms to assess relevant clinical constructs, such as craving and subjective responses to alcohol. However, these controlled paradigms often lack the ecological validity of clinical trials. Therefore, early phase 2 trials can be more efficient and clinically meaningful if they combine the internal validity of experimental laboratory testing with the external validity of clinical trials. To that end, the current study aims to develop and validate a novel early efficacy paradigm, informed by smoking cessation literature, to screen novel medications for AUD. As an established AUD medication, naltrexone will serve as an active control to test both the practice quit attempt model and the efficacy of a promising AUD pharmacotherapy, varenicline.

Methods: Individuals with current AUD reporting intrinsic motivation to change their drinking will complete a week-long "practice quit attempt" while on study medication. Participants are randomized and blinded to either naltrexone, varenicline, or placebo. During the practice quit attempt, participants will complete daily visits over the phone and fill out online questionnaires regarding their drinking, alcohol craving, and mood. Additionally, participants will undergo two alcohol cue-reactivity sessions.

Discussion: The successful completion of this study will advance medications development by proposing and validating a novel early efficacy model for screening AUD pharmacotherapies, which in turn can serve as an efficient strategy for making go/no-go decisions as to whether to proceed with clinical trials.

Trial registration: ClinicalTrials.gov NCT04249882 . Registered on 31 January 2020.

Keywords: Alcohol use disorder; Clinical trial; Medications development; Medications screening; Naltrexone; Varenicline.

Figures

Fig. 1
Fig. 1
Flow diagram illustrating participant’s timeline through the trial

References

    1. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72(8):757. doi: 10.1001/jamapsychiatry.2015.0584.
    1. Rehm J, Dawson D, Frick U, Gmel G, Roerecke M, Shield KD, et al. Burden of disease associated with alcohol use disorders in the United States. Alcohol Clin Exp Res. 2014;38(4):1068–1077. doi: 10.1111/acer.12331.
    1. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, et al. Medications development to treat alcohol dependence: a vision for the next decade: medications development. Addict Biol. 2012;17(3):513–527. doi: 10.1111/j.1369-1600.2012.00454.x.
    1. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003. doi: 10.1001/jama.295.17.2003.
    1. O’Malley SS, O’Connor PG. Medications for unhealthy alcohol use: across the spectrum. Alcohol Res Health. 2011;33(4):300–312.
    1. Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815. doi: 10.1001/jama.2018.11406.
    1. Litten RZ, Falk DE, Ryan ML, Fertig JB. Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development. Alcohol Clin Exp Res. 2016;40(7):1368–1379. doi: 10.1111/acer.13093.
    1. Yardley MM, Ray LA. Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models: medications development. Addict Biol. 2017;22(3):581–615. doi: 10.1111/adb.12349.
    1. Ray LA, Bujarski S, Roche DJO, Magill M. Overcoming the “valley of death” in medications development for alcohol use disorder. Alcohol Clin Exp Res. 2018;42(9):1612–1622. doi: 10.1111/acer.13829.
    1. Bujarski S, Ray LA. Experimental psychopathology paradigms for alcohol use disorders: applications for translational research. Behav Res Ther. 2016;86:11–22. doi: 10.1016/j.brat.2016.05.008.
    1. Perkins K, Lerman C, Stitzer M, Fonte C, Briski J, Scott J, et al. Development of procedures for early screening of smoking cessation medications in humans. Clin Pharmacol Ther. 2008;84(2):216–221. doi: 10.1038/clpt.2008.30.
    1. Perkins KA, Lerman C, Fonte CA, Mercincavage M, Stitzer ML, Chengappa KNR, et al. Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther. 2010;88(1):109–114. doi: 10.1038/clpt.2010.65.
    1. Perkins KA, Lerman C, Karelitz JL, Jao NC, Chengappa KNR, Sparks GM. Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications: screening cessation medications. Addiction. 2013;108(11):1962–1968. doi: 10.1111/add.12273.
    1. Monti PM, Binkoff JA, Abrams DB, Zwick WR, Nirenberg TD, Liepman MR. Reactivity of alcoholics and nonalcoholics to drinking cues. J Abnorm Psychol. 1987;96(2):122–126. doi: 10.1037/0021-843X.96.2.122.
    1. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, et al. Naltrexone’s effect on CUE-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res. 1999;23(8):1386–1394.
    1. Roberts W, Harrison ELR, McKee SA. Effects of varenicline on alcohol cue reactivity in heavy drinkers. Psychopharmacology. 2017;234(18):2737–2745. doi: 10.1007/s00213-017-4667-9.
    1. Niciu MJ, Arias AJ. Targeted opioid receptor antagonists in the treatment of alcohol use disorders. CNS Drugs. 2013;27(10):777–787. doi: 10.1007/s40263-013-0096-4.
    1. Hyytia P, Sinclair JD. Responding for oral ethanol after naloxone treatment by alcohol-preferring AA rats. Alcohol Clin Exp Res. 1993;17(3):631–636. doi: 10.1111/j.1530-0277.1993.tb00810.x.
    1. Mitchell JM, O’Neil JP, Janabi M, Marks SM, Jagust WJ, Fields HL. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci Transl Med. 2012;4(116):116ra6. doi: 10.1126/scitranslmed.3002902.
    1. O’Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, et al. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry. 2015;76(02):e207–e213. doi: 10.4088/JCP.13m08934.
    1. O’Malley S, Krishnan-Sarin S, Farren C, Sinha R, Kreek M. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology. 2002;160(1):19–29. doi: 10.1007/s002130100919.
    1. Richardson K, Baillie A, Reid S, Morley K, Teesson M, Sannibale C, et al. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction. 2008;103(6):953–959. doi: 10.1111/j.1360-0443.2008.02215.x.
    1. Morris PLP, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96(11):1565–1573. doi: 10.1046/j.1360-0443.2001.961115654.x.
    1. Carmen B, Angeles M, Ana M, María AJ. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004;99(7):811–828. doi: 10.1111/j.1360-0443.2004.00763.x.
    1. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2007;64(9):1069. doi: 10.1001/archpsyc.64.9.1069.
    1. Drobes DJ, Anton RF, Thomas SE, Voronin K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004;28(9):1362–1370. doi: 10.1097/01.ALC.0000139704.88862.01.
    1. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol. 2006;70(3):801–805. doi: 10.1124/mol.106.025130.
    1. Blomqvist O, Ericson M, Johnson DH, Engel JA, Söderpalm B. Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur J Pharmacol. 1996;314(3):257–267. doi: 10.1016/S0014-2999(96)00583-3.
    1. Dyr W, Koros E, Bienkowski P, Kostowski W. Involvement of nicotinic acetylcholine receptors in the regulation of alcohol drinking in Wistar rats. Alcohol Alcohol. 1999;34(1):43–47. doi: 10.1093/alcalc/34.1.43.
    1. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an 4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci. 2007;104(30):12518–12523. doi: 10.1073/pnas.0705368104.
    1. McKee SA, Harrison ELR, O’Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009;66(2):185–190. doi: 10.1016/j.biopsych.2009.01.029.
    1. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O’Malley SS. A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology. 2011;215(4):655–663. doi: 10.1007/s00213-010-2160-9.
    1. Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology. 2012;223(3):299–306. doi: 10.1007/s00213-012-2717-x.
    1. Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7(4):277–286. doi: 10.1097/ADM.0b013e31829623f4.
    1. Hwang IK, Morikawa T. Design issues in noninferiority/equivalence trials. Drug Inf J. 1999;33(4):1205–1218. doi: 10.1177/009286159903300424.
    1. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133(6):455. doi: 10.7326/0003-4819-133-6-200009190-00014.
    1. Möller H-J, Broich K. Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. Eur Arch Psychiatry Clin Neurosci. 2010;260(1):3–16. doi: 10.1007/s00406-009-0071-8.
    1. Howick J. Questioning the methodologic superiority of ‘placebo’ over ‘active’ controlled trials. Am J Bioeth. 2009;9(9):34–48. doi: 10.1080/15265160903090041.
    1. Skinner HA, Allen BA. Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol. 1982;91(3):199–209. doi: 10.1037/0021-843X.91.3.199.
    1. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–897. doi: 10.1037/0022-006X.56.6.893.
    1. Beck AT, Steer RA, Brown GK. BDI-II, Beck depression inventory: manual. 2. San Antonio; Boston: Psychological Corp.; Harcourt Brace; 1996. p. 38.
    1. Adamson S, Sellman JD. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev. 2003;22(3):309–315. doi: 10.1080/0959523031000154454.
    1. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Addiction. 1991;86(9):1119–1127. doi: 10.1111/j.1360-0443.1991.tb01879.x.
    1. Mann RE, Sobell LC, Sobell MB, Pavan D. Reliability of a family tree questionnaire for assessing family history of alcohol problems. Drug Alcohol Depend. 1985;15(1–2):61–67. doi: 10.1016/0376-8716(85)90030-4.
    1. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain. 1992;50(2):133–149. doi: 10.1016/0304-3959(92)90154-4.
    1. Miller WR, Tonigan JS, Longabaugh R, National Institute on Alcohol Abuse and Alcoholism (U.S.). The Drinker Inventory of Consequences (DrInC): an instrument for assessing adverse consequences of alcohol abuse: test manual: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism; 1995. (NIH publication). Available from: .
    1. Davis CS, Graham JM. Inventory of drinking situations (IDS): user’s guide. Ontario: Addiction Research Foundation; 1987.
    1. Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen. 1999;128(1):78–87. doi: 10.1037/0096-3445.128.1.78.
    1. Anton RF, Moak DH, Latham P. The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995;19(1):92–99. doi: 10.1111/j.1530-0277.1995.tb01475.x.
    1. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn alcohol craving scale. Alcohol Clin Exp Res. 1999;23(8):1289–1295. doi: 10.1111/j.1530-0277.1999.tb04349.x.
    1. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385. doi: 10.2307/2136404.
    1. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. doi: 10.1016/0165-1781(89)90047-4.
    1. Biener L, Abrams DB. The contemplation ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol. 1991;10(5):360–365. doi: 10.1037/0278-6133.10.5.360.
    1. Verplanken B, Orbell S. Reflections on past behavior: a self-report index of habit strength1. J Appl Social Pyschol. 2003;33(6):1313–1330. doi: 10.1111/j.1559-1816.2003.tb01951.x.
    1. First MB. Structured clinical interview for the DSM (SCID) In: Cautin RL, Lilienfeld SO, editors. The encyclopedia of clinical psychology. Hoboken: Wiley; 2015. pp. 1–6.
    1. Sobell LC, Sobell MB. Timeline follow-back. In: Litten RZ, Allen JP, editors. Measuring alcohol consumption. Totowa: Humana Press; 1992. pp. 41–72.
    1. Grodin EN, Bujarski S, Venegas A, Baskerville W-A, Nieto SJ, Jentsch JD, et al. Reward, relief and habit drinking: initial validation of a brief assessment tool. Alcohol Alcohol. 2019;54(6):574–583. doi: 10.1093/alcalc/agz075.
    1. Cyders MA, Littlefield AK, Coffey S, Karyadi KA. Examination of a short English version of the UPPS-P Impulsive Behavior Scale. Addict Behav. 2014;39(9):1372–1376. doi: 10.1016/j.addbeh.2014.02.013.
    1. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343–381.
    1. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) Addiction. 1989;84(11):1353–1357. doi: 10.1111/j.1360-0443.1989.tb00737.x.
    1. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. AJP. 2011;168(12):1266–1277. doi: 10.1176/appi.ajp.2011.10111704.
    1. Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995;19(3):600–606. doi: 10.1111/j.1530-0277.1995.tb01554.x.
    1. Shacham S. A shortened version of the Profile of Mood States. J Pers Assess. 1983;47(3):305–306. doi: 10.1207/s15327752jpa4703_14.
    1. Drummond DC, Phillips TS. Alcohol urges in alcohol-dependent drinkers: further validation of the Alcohol Urge Questionnaire in an untreated community clinical population. Addiction. 2002;97(11):1465–1472. doi: 10.1046/j.1360-0443.2002.00252.x.
    1. MacKillop J. Factor structure of the alcohol urge questionnaire under neutral conditions and during a cue-elicited urge state. Alcohol Clin Exp Res. 2006;30(8):1315–1321. doi: 10.1111/j.1530-0277.2006.00159.x.
    1. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2005;8(2):267–280. doi: 10.1017/S1461145704004997.
    1. Del Re AC, Maisel N, Blodgett J, Finney J. The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta-analysis. Alcohol Clin Exp Res. 2013;37(6):1064–1068. doi: 10.1111/acer.12067.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner